Inventor
KALAITZIDIS DEMETRIOS
US23 patents
Patents
23 patentsUS10736919B2Aug 11, 2020
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG13 citations94
US11071755B1Jul 27, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG7 citations92
US10881689B2Jan 5, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG7 citations92
US10857184B2Dec 8, 2020
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG9 citations92
US10729725B2Aug 4, 2020
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG7 citations92
US11166985B2Nov 9, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG10 citations86
US11298378B2Apr 12, 2022
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG2 citations84
US11207351B2Dec 28, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG3 citations84
US11202802B2Dec 21, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG2 citations84
US11191783B2Dec 7, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG6 citations84
US11135247B2Oct 5, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG6 citations84
US11013767B2May 25, 2021
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG5 citations84
US11254912B2Feb 22, 2022
Methods and compositions for treating cancer
CRISPR THERAPEUTICS AG5 citations80
US11622977B2Apr 11, 2023
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG1 citations73
US11471491B1Oct 18, 2022
Materials and methods for engineering cells and uses thereof in immuno-oncology
CRISPR THERAPEUTICS AG1 citations73
US11649438B2May 16, 2023
Methods and compositions for treating cancer
CRISPR THERAPEUTICS AG2 citations69
US11679130B2Jun 20, 2023
Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
CRISPR THERAPEUTICS AG1 citations68
US11497773B2Nov 15, 2022
Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
CRISPR THERAPEUTICS AG2 citations68
US12344656B2Jul 1, 2025
Genetically engineered T cells having improved persistence in culture
CRISPR THERAPEUTICS AG0 citations62
US12227763B2Feb 18, 2025
Methods and compositions for treating cancer
CRISPR THERAPEUTICS AG0 citations59
US11389481B2Jul 19, 2022
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
CRISPR THERAPEUTICS AG1 citations59
US11857574B2Jan 2, 2024
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
CRISPR THERAPEUTICS AG0 citations58
US11679131B2Jun 20, 2023
Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
CRISPR THERAPEUTICS AG0 citations58